• Published on: Apr 20, 2020
  • 3 minute read
  • By: Dr Rajan Choudhary

Is Herd Immunity A Valid Strategy For COVID 19?

  • WhatsApp share link icon
  • copy & share link icon
  • twitter share link icon
  • facebook share link icon

Yesterday we explained you what Herd Immunity means and how it works, today we will take the discussion further to determine whether it is effective and can be recommended in the current context. 

COVID-19 currently does not have a cure or a vaccine. Lockdown is the only strategy that appears to be working. Could implementing policies that encourages herd immunity be used to accelerate immunity in the population without the need for a vaccine?

  1. INFECTIVITY

For the strategy to work we need to know a few things about the virus. How infective is it? In one of our earliest blogs we discussed infectivity at length and determined that the R0 (infectivity) may be between 2 and 3. This means each person with the virus can infect around 2-3 people at a time. Whilst this is not as high as Mumps (10-12) it is much higher than the common flu. The higher the R0 the more people that need to be immunised before herd immunity is achieved. For COVID it is estimated that 70% of the population need to be infected.

This is based off our current testing. Due to shortages in testing kits, only testing those that have a high likelihood of being infected and poorly organised testing infrastructure in some countries, we are likely underestimating. The number of people infected may be much higher as we are missing those that are asymptomatic but still have the disease and are still passing the disease on.

  1. MORTALITY

Secondly, we need to know the mortality from COVID-19. Early estimates of mortality were as high as 10%, as we had little data on how many people were truly infected, but as the number of infected cases rose, and testing amongst the infected and symptomatic population rose, a more accurate mortality has been found to be around 1%. There is a risk we may still be underestimating the true mortality, as some cities have noted a spike in cardiac deaths, and some evidence supports possible cardiac damage due to COVID. But from the data we have, we know its mortality is lower than MERS (34%) and SARS (10%) but more than influenza (0.1%).

estimates of the COVID-19 case fatality rate

Whilst we have some data on who is likely to suffer from severe COVID symptoms (elderly, immunocompromised, people with heart or lung problems) we still cannot accurately determine who will get severe COVID in the “low risk” population. Simply because someone is young and healthy does not mean they will not die from COVID.

  1. LENGTH OF IMMUNITY

Third we need to know how long this immunity will last. Similar coronaviruses responsible for the common cold usually create immunity that lasts for a few months, which is why we often get the cold repeatedly. A virus is also very prone to mutations that can change the structure and functions of its proteins, proteins responsible for tagging, latching on to and entering cells. If the structure of these proteins changes enough, then our antibodies will not be able to bind on, and new types of antibodies will have to be made with a slightly different structure. This effectively means our bodies have to start from step 1 again to create immunity, and we have to make new vaccines. This mutation rate is why we have to make new vaccines every season for the flu.

  1. LONG TERM COMPLICATIONS

Finally, we need to know if there are any long-term implications from a viral infection. Again, this is something we do not know yet, as the virus has only been around for a few months. There may be implications for the cardiovascular system, long term breathing problems or more. And even if the complication rate appears relatively low (say, 1%), if millions of people are allowed to get infected, by definitions thousands or tens of thousands of people will have these complications, complications that can lead to issues later in life or an early death.

CONCLUSION

So, is herd immunity a viable strategy for COVID? Without a safe vaccine the general consensus appears to be no.

We don’t know how infective the virus really is or how many people it has infected

A    1%     death rate is still very high. This means for every 100 people to be infected; one will die. This would mean hundreds of thousands of people dead in a country with a population over 10 million. It is unacceptably high.

If the death rate is 1%, then hospitalisation rate is likely higher. Almost all countries do not have capacity to have 1% of the population in hospital. Overwhelming the healthcare system will lead to poorer care, and worse care for those who do not have COVID. Leading to more people coming to serious harm or dying as a result of poor healthcare, not because of COVID.

We don’t know the long-term effects of COVID. By purposefully infecting people instead of waiting for a vaccine we may be causing unnecessary damage to a person’s health that only becomes apparent later in life. But this is speculation as we do not currently know if COVID has long term effects,

We don’t know if all of the risks above will amount to anything. The immunity may not last long enough, leading to another spike in infections and mortality.

Mass vaccination appears to be the safest strategy. And though human clinical trials have started on a number of vaccines, we are still months away from deployment.  Until then we should not come out of lockdown prematurely, not until we have received an unbiased assessment from public health officials that states it is safe.

Read Blog
Monkeypox

Monkeypox Virus Symptoms: Early Signs, Disease Progression, and When to Seek Care

Monkeypox, now commonly referred to as mpox, is a viral infection that has gained global attention due to outbreaks beyond traditionally affected regions. Understanding monkeypox virus symptoms is essential for early detection, timely isolation and prevention of further spread.

According to the World Health Organization and Indian public health authorities, awareness of symptom patterns plays a critical role in controlling outbreaks and protecting vulnerable populations.

What Is the Monkeypox Virus?

Monkeypox is caused by the monkeypox virus, a member of the Orthopoxvirus family, which also includes smallpox. While generally less severe than smallpox, monkeypox can still cause significant illness and discomfort.

The virus spreads primarily through close physical contact.

 

Incubation Period of Monkeypox

After exposure, symptoms typically appear within:

  • 5 to 21 days

  • most commonly 6 to 13 days

Individuals may feel well during this period but can become infectious once symptoms begin.

 

Early Monkeypox Virus Symptoms

Fever

Fever is usually the first symptom and may be:

  • sudden in onset

  • moderate to high grade

  • accompanied by chills

Fever signals the start of systemic infection.

 

Headache and Body Aches

Patients often experience:

  • severe headache

  • muscle aches

  • back pain

These symptoms resemble many viral illnesses.

 

Fatigue and Weakness

Marked tiredness and low energy levels are common and may limit daily activities.

 

Swollen Lymph Nodes

Swollen lymph nodes are a distinguishing feature of monkeypox.

Common sites include:

  • neck

  • armpits

  • groin

This helps differentiate monkeypox from chickenpox or smallpox.

Development of Monkeypox Rash

The skin rash usually appears:

  • 1 to 3 days after fever onset

It may begin on the face or genital area and spread to other parts of the body.

 

Stages of Monkeypox Rash

The rash progresses through well-defined stages:

Macules

Flat red spots on the skin.

Papules

Raised, firm bumps.

Vesicles

Fluid-filled blisters.

Pustules

Pus-filled lesions that are painful.

Scabs

Lesions crust over and eventually fall off.

Complete healing occurs once scabs detach.

 

Distribution of Rash

Rash commonly affects:

  • face

  • hands and feet

  • mouth

  • genital and anal areas

The number of lesions can vary widely.

 

Pain and Discomfort

Rash lesions may be:

  • painful

  • itchy during healing

Pain severity differs between individuals.

 

Other Possible Symptoms

Additional symptoms may include:

  • sore throat

  • cough

  • nasal congestion

These reflect upper respiratory involvement.

 

Duration of Illness

Monkeypox symptoms typically last:

  • 2 to 4 weeks

Recovery occurs gradually as lesions heal.

 

Who Is at Higher Risk of Severe Illness?

Higher risk groups include:

  • children

  • pregnant women

  • individuals with weakened immunity

  • people with chronic illness

Early care is crucial in these groups.

 

Complications of Monkeypox

Though uncommon, complications may include:

  • secondary bacterial skin infections

  • dehydration

  • pneumonia

  • eye involvement

Prompt medical guidance reduces risk.

 

How Monkeypox Is Transmitted

Transmission occurs through:

  • direct skin-to-skin contact

  • contact with lesions or bodily fluids

  • respiratory droplets during close contact

  • contaminated clothing or bedding

Understanding transmission helps prevent spread.

 

When to Seek Medical Care

Seek medical evaluation if:

  • fever is followed by rash

  • lymph nodes become swollen

  • rash appears in genital or facial areas

Early diagnosis supports isolation and care.

 

Diagnosis and Testing

Diagnosis may involve:

  • clinical examination

  • laboratory testing of lesion samples

Public health authorities guide testing protocols.

 

Prevention and Control Measures

Preventive steps include:

  • avoiding close contact with infected individuals

  • maintaining good hand hygiene

  • isolating during illness

  • following public health guidance

Vaccination may be recommended for high-risk groups.

 

Role of Public Awareness

Awareness of symptoms:

  • enables early detection

  • reduces stigma

  • supports timely care

WHO emphasises community education in outbreak control.

 

Conclusion

Monkeypox virus symptoms typically begin with fever, body aches and swollen lymph nodes, followed by a characteristic rash that progresses through defined stages. While most cases are self-limiting, early recognition, medical evaluation and isolation are essential to prevent complications and reduce transmission. Staying informed and acting promptly protects both individual and public health.

 

References

  • World Health Organization (WHO) – Mpox (Monkeypox) Clinical and Public Health Guidance

  • Indian Council of Medical Research (ICMR) – Emerging Viral Infections Reports

  • National Centre for Disease Control (NCDC), India – Monkeypox Advisories

  • Lancet – Clinical Features and Outcomes of Mpox

  • NITI Aayog – Public Health Preparedness and Infectious Disease Control

See all

Live Doctor consultation
Live Doctor Chat

Download Our App & Get Consultation from anywhere.

App Download
call icon for mobile number calling and whatsapp at secondmedic